On Nov 13, major Wall Street analysts update their ratings for $Natera (NTRA.US)$, with price targets ranging from $160 to $175.
J.P. Morgan analyst Rachel Vatnsdal maintains with a buy rating, and adjusts the target price from $135 to $160.
TD Cowen analyst Daniel Brennan maintains with a buy rating, and adjusts the target price from $145 to $175.
Baird analyst Catherine Ramsey Schulte maintains with a buy rating, and adjusts the target price from $120 to $160.
CCORF analyst Kyle Mikson CFA maintains with a buy rating, and adjusts the target price from $150 to $165.
Furthermore, according to the comprehensive report, the opinions of $Natera (NTRA.US)$'s main analysts recently are as follows:
Natera has delivered another robust quarter, according to an analyst. With a strong performance across volume, selling price, margin, and cash management, the company is perceived as operating effectively, with potential for further enhancement leading into 2025. The consensus is that Natera stands out as one of the most distinguished entities in the diagnostics sector.
Natera's Q3 results significantly exceeded expectations, continuing to enhance its core fundamentals. The company is strategically reinvesting its operating cash flow back into the business, which is strengthening its position in sales, marketing, medical affairs, and legal aspects.
The company recorded another robust quarter with its sales, margins, and cash flow all surpassing expectations.
Natera's third quarter revenue and gross margins exceeded estimates, showing robust performance. The company's progress is widespread, highlighted by a 60% annual increase in Signatera clinical volume growth and significant gains within women's health accounts.
Here are the latest investment ratings and price targets for $Natera (NTRA.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月13日，多家華爾街大行更新了$Natera (NTRA.US)$的評級，目標價介於160美元至175美元。
摩根大通分析師Rachel Vatnsdal維持買入評級，並將目標價從135美元上調至160美元。
TD Cowen分析師Daniel Brennan維持買入評級，並將目標價從145美元上調至175美元。
貝雅分析師Catherine Ramsey Schulte維持買入評級，並將目標價從120美元上調至160美元。
CCORF分析師Kyle Mikson CFA維持買入評級，並將目標價從150美元上調至165美元。
此外，綜合報道，$Natera (NTRA.US)$近期主要分析師觀點如下：
根據分析師的說法，natera再次交出了強勁的一個季度。公司在成交量、銷售價格、利潤率和現金管理方面表現強勁，被視爲有效運營，有進一步提升潛力，預計將在2025年前期領先。市場共識認爲，natera在診斷領域中脫穎而出，被視爲最傑出的實體之一。
natera的第三季度業績大幅超出預期，持續增強其核心基本面。公司正策略性將經營現金流重新投入業務中，加強在銷售、營銷、醫療事務和法務等方面的地位。
公司再次交出了一個強勁的季度，銷售額、利潤率和現金流均超出預期。
natera第三季度的營業收入和毛利超過了預期，表現強勁。公司的進展普遍良好，Signatera臨床成交量增長年增60%，在婦女健康帳戶中取得顯著收益。
以下爲今日4位分析師對$Natera (NTRA.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
